Table 1.
Baseline characteristics, laboratory data, and single nucleotide polymorphisms of the vitamin D receptor gene of patients included in the study
|
|
Before treatment initiation
|
P value
|
At delivery after treatment
|
P value
|
||
|
Full responders (n = 23)
|
Partial responders (n = 15)
|
Full responders (n = 23)
|
Partial responders (n = 15)
|
|||
| Age, yr, mean ± SD | 29.09 ± 3.55 | 28.73 ± 3.01 | 0.75 | NA | NA | |
| BMI, kg/m2, mean ± SD | 23.15 ± 3.33 | 21.42 ± 3.61 | 0.14 | NA | NA | |
| Season of blood draw | 0.552 | 0.311 | ||||
| Winter or spring | 10 (43.5%) | 8 (53.3%) | 16 (69.6%) | 8 (53.3%) | ||
| Summer or autumn | 13 (56.5%) | 7 (46.7%) | 7 (30.4%) | 7 (46.7%) | ||
| HBsAg log10 IU/mL mean (IQR) | 4.33 (3.73, 4.52) | 4.36 (4.1, 4.72) | 0.663 | 4.11 (2.56, 5.44) | 4.33 (3.95, 4.56) | 0.256 |
| HBeAg log10 IU/mL mean (IQR) | 3.16 (2.66, 3.2) | 3.16 (3.12, 3.19) | 0.928 | 3.18 (2.85, 3.19) | 6.75 (6.21, 8.49) | 0.510 |
| HBV DNA, log10 mean (IQR) | 8.06 (7.61, 8.44) | 8.09 (7.53, 8.16) | 0.56 | 3.61 (2.88, 4.46) | 7.41 (5.79, 7.9) | < 0.0001 |
| Vitamin D, ng/mL, mean ± SD | 25.44 ± 9.42 | 17.66 ± 5.34 | 0.006 | 26.76 ± 8.59 | 21.24 ± 6.88 | 0.044 |
| ≥ 30 | 8 (34.8%) | 1 (6.7%) | 0.021 | 10 (43.5%) | 2 (13.3%) | 0.127 |
| 20-30 | 8 (34.8%) | 3 (20%) | 6 (26.1%) | 6 (40%) | ||
| < 20 | 7 (30.4%) | 11 (73.3%) | 7 (30.4%) | 7 (46.7%) | ||
| Hemoglobin, g/dL, mean ± SD | 113.78 ± 9.29 | 115.47 ± 8.98 | 0.583 | 114.3 ± 12.78 | 118 ± 10.17 | 0.353 |
| WBC count, × 106/µL, mean ± SD | 7.83 ± 1.54 | 8.61 ± 2.26 | 0.282 | 7.63 ± 1.77 | 7.7 ± 2.17 | 0.918 |
| Platelet, × 103/µL, mean ± SD | 149.52 ± 56.73 | 155.6 ± 53.01 | 0.742 | 137.17 ± 53.92 | 149.4 ± 56.21 | 0.506 |
| Neutrophil, mean ± SD | 5.78 ± 1.38 | 6.51 ± 2.0 | 0.289 | 5.33 ± 1.62 | 5.53 ± 1.96 | 0.731 |
| Lymphocyte, mean ± SD | 1.46 ± 0.4 | 1.49 ± 0.49 | 0.823 | 1.63 ± 1.14 | 1.61 ± 0.49 | 0.964 |
| Total bilirubin, mg/dL, mean ± SD | 14.73 ± 3.24 | 13.61 ± 3.09 | 0.299 | 14.97 ± 4.15 | 17.13 ± 4.23 | 0.128 |
| Albumin, g/dL, mean ± SD | 39.21 ± 2.36 | 39.93 ± 2.28 | 0.355 | 26.42 ± 3.19 | 37.33 ± 3.68 | 0.698 |
| ALT, U/L, mean (IQR) | 22 (19, 28) | 21 (15, 32) | 0.891 | 22 (18, 30) | 21 (17, 36) | 0.893 |
| Triglyceride, mg/dL, mean (IQR) | 1.74 (1.59, 2.38) | 1.58 (1.34, 1.79) | 0.189 | 3.06 (2.41, 3.67) | 2.52 (2.03, 3.21) | 0.131 |
| Cholesterol, mg/dL, mean ± SD | 5.33 ± 0.85 | 5.7 ± 1.97 | 0.347 | 4.87 ± 0.79 | 5.56 ± 0.96 | 0.001 |
| Creatinine, mg/dL, mean (IQR) | 43 (38, 49) | 43 (39, 45) | 0.951 | 44 (37, 51) | 47.5 (39.8, 55) | 0.397 |
| Alkaline phosphatase, U/L, mean (IQR) | 7 (5, 10) | 10 (4, 23) | 0.234 | 48 (19, 72) | 52 (47, 111) | 0.199 |
| GGT, U/L, mean ± SD | 12.91 ± 8.1 | 13.87 ± 8.4 | 0.675 | 14.48 ± 7.57 | 22 ± 15.19 | 0.115 |
| VDR SNPs | ||||||
| Cdx2 TT | 9 (39.1%) | 2 (13.3%) | 0.076 | NA | ||
| TC/CC | 14 (30.9%) | 13 (86.7%) | ||||
| Bsm1 CC | 20 (87%) | 13 (86.7%) | 0.979 | NA | ||
| CT/TT | 3 (13%) | 2 (13.3%) | ||||
| Fokl AA/AG | 18 (78.3%) | 10 (66.7%) | 0.431 | NA | ||
| GG | 5 (21.7%) | 5 (33.3%) | ||||
| Taq1 AA | 15 (65.2%) | 9 (60%) | 0.744 | NA | ||
| AG/GG | 8 (34.8%) | 6 (40%) | ||||
| Apa1 CC | 10 (43.5%) | 7 (46.7%) | 0.847 | NA | ||
| CA/AA | 13 (56.5%) | 8 (53.3%) | ||||
VDR SNPs: Single nucleotide polymorphisms of the vitamin D receptor gene; BMI: Body mass index; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; WBC: White blood cell; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; IQR: Interquartile range; NA: Not available.